PATIENT SUPPORT

You and your family are not alone

When you and your doctor decide to start treatment with OXLUMO™, we're here for you with personalized assistance offerings and support.

Alnylam Assist

Alnylam Assist® is here to help

Alnylam offers a personalized support program for patients receiving OXLUMO. Our services include:
 

  • Help navigating your insurance benefits
  • A dedicated support team that can help answer questions about insurance, getting started on treatment, and locating additional primary hyperoxaluria type 1 (PH1) resources
  • Financial assistance: Patients who qualify may be eligible for commercial copay assistance or other financial assistance programs*
  • Help with getting started on treatment: once you and your doctor fill out a Start Form, our case managers will help you access OXLUMO
     

Individuals must meet specified criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

 

We’re here for you. As you begin treatment with OXLUMO, Alnylam Assist® will provide you with a dedicated Alnylam Case Manager throughout your treatment. A trained Patient Education Liaison (PEL) is also available to help you learn more about PH1 and OXLUMO.

Get started with Alnylam Assist® today.

Visit AlnylamAssist.com

Image

In-home nursing support

If your insurance coverage allows, you may be able to have a healthcare professional administer OXLUMO in your home.

We’re here to help. Please reach out with questions.

For Alnylam Assist®Call: 1-833-256-2748 Monday-Friday, 8 AM-6 PM ET

Please call Alnylam Assist® to find out if you may be eligible for at‑home administration based on your insurance coverage.

Frequently asked questions about OXLUMO

Who can take OXLUMO?

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine in children and adults. Your doctor will determine if OXLUMO is right for you.

What is OXLUMO and how does it work?
  • OXLUMO is a prescription medicine for the treatment of PH1 to lower oxalate in urine in children and adults
  • OXLUMO targets the GO enzyme—a liver enzyme involved in making oxalate
  • OXLUMO reduces levels of the GO enzyme so that less oxalate is made and sent to the kidneys
What are the most common side effects of OXLUMO?

The most common side effects of OXLUMO are injection site reaction (including redness, pain, itching, or swelling at the site of the injection) and abdominal pain (including stomach pain or discomfort). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

How is OXLUMO given?

OXLUMO is an injection administered by a healthcare provider. OXLUMO is injected under the skin. Injection sites can include the area under the skin on the abdomen, thighs, or upper arms.

Dosing of OXLUMO is based on the patient's weight. Dosing happens in 2 phases:

  • 3 starting doses are given 1 month apart at the start of treatment to help bring urinary oxalate levels down

  • Ongoing dosing begins 1 month after the last starting dose to help keep urinary oxalate levels down

    • For patients weighing 10 kg (22 lb) or more, the frequency of dosing is 1 dose given every 3 months (4 doses per year)

    • Children under 10 kg (22 lb) will receive 1 dose every month

OXLUMO can cause injection site reactions. Symptoms included redness, pain, itching, or swelling at the site of injection.

How can Alnylam Assist® help me?

Alnylam Assist® is here to help patients who are prescribed OXLUMO.

Resources available through Alnylam Assist® include:

  • Help navigating your insurance benefits
  • Financial assistance, including commercial copay assistance or other financial assistance programs for eligible patients*
  • A dedicated support team that can help answer questions about insurance, getting started on treatment, and locating additional primary hyperoxaluria type 1 (PH1) resources

A dedicated case manager is available throughout your treatment journey. A trained Patient Education Liaison (PEL) is available to help you learn more about PH1 and OXLUMO. Visit the Alnylam Assist® website to learn more.

Individuals must meet specified criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

Take Me to Alnylam Assist®

Other resources and organizations

You and your family may find the following sites and organizations helpful.

Image
Oxalosis and Hyperoxaluria Foundation Logo

Visit Site

Image
American Kidney Fund Logo

Visit Site

Image
National Kidney Foundation Logo

Visit Site

We hope you find the resources mentioned here helpful. Alnylam Pharmaceuticals is not affiliated with these organizations. By listing these resources, Alnylam Pharmaceuticals is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided for informational purposes and should not replace your doctor’s medical advice.

Image

CONNECT WITH AN EDUCATOR

Learn about PH1 and treatment with OXLUMO from a trained patient educator.

Let's Connect

IMPORTANT SAFETY INFORMATION

The most common side effect of OXLUMO™ (lumasiran) is injection site reaction (redness, pain, itching, and swelling at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

WHAT IS OXLUMO?

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine in children and adults.  

For additional information about OXLUMO, please see full Prescribing Information.